EHA 2017 | Is venetoclax in combination with low-dose cytarabine a safe regimen for the treatment of AML?
Andrew Wei
• 24 Jun 2017
Andrew Wei, MBBS, PhD, FRACP, FRCPA, from Monash University, Victoria, Australia, discusses the safety and efficacy of venetoclax in combination with low-dose cytarabine for the treatment of acute myeloid leukemia in elderly patients, at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain. He describes some of the side effects of the combination regimen, particularly in causing suppression of the bone marrow, but also points out the many advantages that this regimen has compared to previous therapeutic strategies. He explains that although a Phase III trial has commenced, it will be at least a few years until results are achieved due to the large size of the trial.
